Lenti-D gene therapy: Preliminary Phase I data

Preliminary data from a French Phase I trial in 2 patients with ALD showed that Lenti-D gene therapy led to polyclonal reconstitution in both patients at 24-30 months of follow-up, with 9-14% of granu...